NanoViricides, Inc. (NYSEAM: NNVC)
Health Care · Biotechnology · US
$1.38
+6.15% today · -8.0% 1Y
NanoViricides, Inc. (NYSEAM: NNVC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $35.22M and employs 7 people.
Over the last twelve months the share price has lost 8.0%, trading between 0.85 and 2.23.
Tweenvest scores NanoViricides, Inc. across four factors: quality 35/100, value 94/100. Its strongest factor is value.
NNVC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $35.22M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.41
- Dividend yield
- —
- Beta (5Y)
- 1.79
- 52-week high
- $2.23
- 52-week low
- $0.85
- Avg volume (3M)
- —
- Shares outstanding
- 25.52M
- Employees
- 7
- Next earnings
- —
About NanoViricides, Inc.
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
- ISIN
- US6300873022
- Founded
- 2005
- Listed since
- Oct 26, 2005
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Enimmune CorporationTPEX: 6564 | $36.35M | NT$16.35 | -0.61% |
| Mendus AB (publ)OM: IMMU | $36.16M | Skr5.40 | -6.09% |
| Actinium Pharmaceuticals, Inc.NYSEAM: ATNM | $35.53M | $1.13 | +2.73% |
| Transcenta Holding LimitedSEHK: 6628 | $35.36M | HK$0.65 | -19.75% |
| Elutia Inc.NasdaqCM: ELUT | $35.17M | $0.79 | -3.54% |
| Lite Strategy, Inc.NasdaqCM: LITS | $34.97M | $1.15 | -9.45% |
| Holy Stone Healthcare Co., Ltd.TPEX: 4194 | $34.87M | NT$7.75 | -4.32% |
| Edesa Biotech, Inc.NasdaqCM: EDSA | $34.72M | $2.57 | -26.78% |
Figures last refreshed Oct 18, 2026.